Enliven Therapeutics, Inc.
ELVN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001672619
In the last 90 days, Enliven Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 214 institutions reported holding it in 13F filings for Q2 2026, worth $4.06B in total; no superinvestor holds it.
13F holders, Q1 2023
Institutional positions in Enliven Therapeutics, Inc. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 45
- +9 vs. Q4 2022
- Shares held
- 33.6M
- +15.3M (+84.0%) vs. Q4 2022
- Total value
- $735.0M
- +$660.3M (+884.5%) vs. Q4 2022
- New holders
- 17
- 5 more added
- Sold out
- 8
- 23 more reduced
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ELVN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 214 | $4.06B |
| Q1 2026 | 171 | $2.43B |
| Q4 2025 | 126 | $960.9M |
| Q3 2025 | 134 | $1.22B |
| Q2 2025 | 125 | $1.19B |
| Q1 2025 | 122 | $983.9M |
| Q4 2024 | 114 | $1.12B |
| Q3 2024 | 102 | $1.22B |
| Q2 2024 | 93 | $1.13B |
| Q1 2024 | 74 | $780.8M |
| Q4 2023 | 62 | $539.8M |
| Q3 2023 | 61 | $533.8M |
| Q2 2023 | 63 | $797.9M |
| Q1 2023 | 45 | $735.0M |
| Q4 2022 | 36 | $74.7M |
| Q3 2022 | 31 | $18.8M |
| Q2 2022 | 26 | $13.1M |
| Q1 2022 | 31 | $26.2M |
| Q4 2021 | 35 | $33.6M |
| Q3 2021 | 38 | $62.5M |
| Q2 2021 | 31 | $86.3M |
| Q1 2021 | 40 | $92.9M |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Enliven Therapeutics, Inc.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Wells Fargo & Company | 24 | $526 | 0.00% | −73−75.3% | Reduced |
| Baystate Wealth Management LLC | 50 | $1.09K | 0.00% | +50 | New |
| JPMorgan Chase & Co | 94 | $2.00K | 0.00% | +94 | New |
| Federated Hermes, Inc. | 243 | $5.32K | 0.00% | −797−76.6% | Reduced |
| Point72 Middle East FZE | 293 | $6.42K | 0.00% | +293 | New |
| UBS Group AG | 334 | $7.32K | 0.00% | −2,511−88.3% | Reduced |
| Royal Bank of Canada | 486 | $11.0K | 0.00% | −102−17.3% | Reduced |
| Point72 Asset Management, L.P. | 746 | $16.3K | 0.00% | +746 | New |
| Dorsey Wright & Associates | 1,237 | $27.1K | 0.01% | −4,263−77.5% | Reduced |
| Tower Research Capital LLC (TRC) | 1,657 | $36.0K | 0.00% | −2,177−56.8% | Reduced |
| Prelude Capital Management, LLC | 34,062 | $40.0K | 0.00% | −27,080−44.3% | Reduced |
| Bank of America Corp | 6,545 | $143.3K | 0.00% | +6,315+2,745.7% | Added |
| Barclays PLC | 7,227 | $158.3K | 0.00% | +7,227 | New |
| Cubist Systematic Strategies, LLC | 8,986 | $196.8K | 0.00% | −3,814−29.8% | Reduced |
| State Street Corp | 9,424 | $206.4K | 0.00% | −28,274−75.0% | Reduced |
| Dimensional Fund Advisors LP | 9,915 | $217.1K | 0.00% | −25,976−72.4% | Reduced |
| Citigroup Inc | 11,263 | $246.7K | 0.00% | +11,263 | New |
| Mirabella Financial Services LLP | 11,670 | $255.6K | 0.05% | +11,670 | New |
| Bank of New York Mellon Corp | 15,295 | $335.0K | 0.00% | −36,732−70.6% | Reduced |
| Susquehanna International Group, LLP | 17,167 | $376.0K | 0.00% | +17,167 | New |
| Morgan Stanley | 17,418 | $381.5K | 0.00% | −39,330−69.3% | Reduced |
| Bridgeway Capital Management, LLC | 17,950 | $393.1K | 0.01% | −81,750−82.0% | Reduced |
| Jane Street Group, LLC | 18,444 | $403.9K | 0.00% | +18,444 | New |
| Acuta Capital Partners, LLC | 30,979 | $678.4K | 0.53% | −13,524−30.4% | Reduced |
| BlackRock Inc. | 33,795 | $740.1K | 0.00% | −80,755−70.5% | Reduced |
| Geode Capital Management, LLC | 35,388 | $775.0K | 0.00% | −102,338−74.3% | Reduced |
| Goldman Sachs Group Inc | 41,411 | $906.9K | 0.00% | +41,411 | New |
| Millennium Management LLC | 46,874 | $1.03M | 0.00% | +46,874 | New |
| JBF Capital, Inc. | 50,050 | $1.10M | 0.25% | −150,150−75.0% | Reduced |
| Renaissance Technologies LLC | 70,258 | $1.54M | 0.00% | −143,542−67.1% | Reduced |
| Vanguard Group Inc | 151,914 | $3.33M | 0.00% | −289,299−65.6% | Reduced |
| BML Capital Management, LLC | 212,179 | $4.65M | 4.02% | −2,805,595−93.0% | Reduced |
| Logos Global Management LP | 401,229 | $8.79M | 1.26% | +401,229 | New |
| Janus Henderson Group PLC | 602,154 | $13.2M | 0.01% | −326,552−35.2% | Reduced |
| Boxer Capital, LLC | 710,644 | $15.6M | 0.76% | +710,644 | New |
| Frazier Life Sciences Management, L.P. | 830,983 | $18.2M | 1.32% | +830,983 | New |
| Commodore Capital LP | 1,731,365 | $37.9M | 5.77% | −763,429−30.6% | Reduced |
| Fairmount Funds Management LLC | 1,924,938 | $42.2M | 7.25% | +1,293,605+204.9% | Added |
| Cormorant Asset Management, LP | 1,936,133 | $42.4M | 2.79% | +1,936,133 | New |
| Ra Capital Management, L.P. | 2,122,465 | $46.5M | 1.05% | −1,128,259−34.7% | Reduced |
| VR Adviser, LLC | 2,214,142 | $48.5M | 9.47% | +2,214,142 | New |
| Citadel Advisors LLC | 2,296,210 | $50.3M | 0.05% | +1,519,425+195.6% | Added |
| FMR LLC | 3,163,482 | $69.3M | 0.01% | +3,068,137+3,217.9% | Added |
| 5AM Venture Management, LLC | 5,798,475 | $127.0M | 32.47% | +5,798,475 | New |
| OrbiMed Advisors LLC | 8,996,213 | $197.0M | 3.90% | +4,609,645+105.1% | Added |
| Woodline Partners LP | 0 | $0 | 0.00% | −866,405−100.0% | Sold out |
| Diametric Capital, LP | 0 | $0 | 0.00% | −171,942−100.0% | Sold out |
| Marquette Asset Management, LLC | 0 | $0 | 0.00% | −37,745−100.0% | Sold out |
| Northern Trust Corp | 0 | $0 | 0.00% | −26,697−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −25,700−100.0% | Sold out |
| Great Valley Advisor Group, Inc. | 0 | $0 | 0.00% | −13,660−100.0% | Sold out |
| Charles Schwab Investment Management Inc | 0 | $0 | 0.00% | −11,519−100.0% | Sold out |
| Freedom Wealth Alliance, LLC | 0 | $0 | 0.00% | −3,100−100.0% | Sold out |